PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas

Emerging results support the concept that Alzheimer disease (AD) and age-related dementia are affected by the ability of the immune system to contain the brain's pathology. Accordingly, well-controlled boosting, rather than suppression of systemic immunity, has been suggested as a new approach to modify disease pathology without directly targeting any of the brain's disease hallmarks. Here, we provide a short review of the mechanisms orchestrating the cross-talk between the brain and the immune system. We then discuss how immune checkpoint blockade directed against the PD-1/PD-L1 pathways could be developed as an immunotherapeutic approach to combat this disease using a regimen that will address the needs to combat AD.

Download Full-text

Potential immunotherapy for Alzheimer disease and age-related dementia

Dialogues in Clinical Neuroscience ◽

10.31887/dnc.2019.21.1/mschwartz ◽

2019 ◽

Vol 21 (1) ◽

pp. 21-25 ◽

Cited By ~ 1

Keyword(s):

Immune System ◽

Alzheimer Disease ◽

Cross Talk ◽

Immune Checkpoint ◽

Short Review ◽

Immune Checkpoint Blockade ◽

Checkpoint Blockade ◽

New Approach ◽

Age Related ◽

The Brain

Emerging results support the concept that Alzheimer disease (AD) and age-related dementia are affected by the ability of the immune system to contain the brain’s pathology. Accordingly, well-controlled boosting, rather than suppression of systemic immunity, has been suggested as a new approach to modify disease pathology without directly targeting any of the brain’s disease hallmarks. Here, we provide a short review of the mechanisms orchestrating the cross-talk between the brain and the immune system. We then discuss how immune checkpoint blockade directed against the PD-1/PD-L1 pathways could be developed as an immunotherapeutic approach to combat this disease using a regimen that will address the needs to combat AD.

Download Full-text

Faculty Opinions recommendation of Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726046371.793541844 ◽

2018 ◽

Author(s):

Maurie Markman

Keyword(s):

Immune Checkpoint ◽

Immune Checkpoint Blockade ◽

Position Paper ◽

Checkpoint Blockade

Download Full-text

Faculty Opinions recommendation of Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726735651.793550870 ◽

2018 ◽

Author(s):

Xiaojing Ma

Keyword(s):

Ovarian Cancer ◽

Dendritic Cells ◽

Immune Checkpoint ◽

Late Stage ◽

Immune Checkpoint Blockade ◽

Checkpoint Blockade ◽

Stimulatory Capacity

Download Full-text

Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach

British Journal of Cancer ◽

10.1038/s41416-021-01285-1 ◽

2021 ◽

Author(s):

Sarah N. Lauder ◽

Bart Vanhaesebroeck ◽

Awen Gallimore

Keyword(s):

Immune Checkpoint ◽

Immune Checkpoint Blockade ◽

Solid Tumours ◽

Checkpoint Blockade ◽

Tumour Control ◽

Anti Cancer ◽

Clinical Models

SummaryEmerging studies have demonstrated the potential of PI3Kδ blockade as an immunotherapy for solid tumours. In pre-clinical models, we recently demonstrated that anti-LAG3 immune checkpoint blockade vastly potentiated PI3Kδ-based immunotherapy, enabling successful tumour control in all treated mice.

Download Full-text